Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Ludolph

Showing results (81-90 of 119) with videos related to

Pageof 12
Sort By:
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 15, 2026
Innate immune signaling as a potential pathomechanistic biomarker for distinct subtypes in amyotrophic lateral sclerosisMarcel Naumann, Stefanie Kretschmer, Johannes Dorst, et al.
The Lancet. Neurology|October 20, 2018
Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trialChristopher Grunseich, Ram Miller, Therese Swan, et al.
Brain Communications|April 4, 2023
Structural correlates of language processing in primary progressive aphasiaCurtiss A Chapman, Maryna Polyakova, Karsten Mueller, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|January 5, 2012
Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALSMarkus Otto, Robert Bowser, Martin Turner, et al.
The EMBO Journal|June 8, 2018
NF-κB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALSNajwa Ouali Alami, Christine Schurr, Florian Olde Heuvel, et al.
The Lancet. Neurology|February 1, 2017
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trialVincent Meininger, Angela Genge, Leonard H van den Berg, et al.
BMC Neurology|January 3, 2023
PREDICT-juvenile-stroke: PRospective evaluation of a prediction score determining individual clinical outcome three months after ischemic stroke in young adults - a study protocolSonja Schönecker, Verena Hoffmann, Fady Albashiti, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 31, 2021
Quantifying progression in primary progressive aphasia with structural neuroimagingJolina Lombardi, Benjamin Mayer, Elisa Semler, et al.
European Journal of Neurology|March 12, 2024
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD)Philip Van Damme, Ammar Al-Chalabi, Peter M Andersen, et al.
Nature Communications|March 27, 2025
CREB3 gain of function variants protect against ALSSalim Megat, Christine Marques, Marina Hernán-Godoy, et al.
Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 15, 2026
Innate immune signaling as a potential pathomechanistic biomarker for distinct subtypes in amyotrophic lateral sclerosisMarcel Naumann, Stefanie Kretschmer, Johannes Dorst, et al.
The Lancet. Neurology|October 20, 2018
Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trialChristopher Grunseich, Ram Miller, Therese Swan, et al.
Brain Communications|April 4, 2023
Structural correlates of language processing in primary progressive aphasiaCurtiss A Chapman, Maryna Polyakova, Karsten Mueller, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|January 5, 2012
Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALSMarkus Otto, Robert Bowser, Martin Turner, et al.
The EMBO Journal|June 8, 2018
NF-κB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALSNajwa Ouali Alami, Christine Schurr, Florian Olde Heuvel, et al.
The Lancet. Neurology|February 1, 2017
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trialVincent Meininger, Angela Genge, Leonard H van den Berg, et al.
BMC Neurology|January 3, 2023
PREDICT-juvenile-stroke: PRospective evaluation of a prediction score determining individual clinical outcome three months after ischemic stroke in young adults - a study protocolSonja Schönecker, Verena Hoffmann, Fady Albashiti, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 31, 2021
Quantifying progression in primary progressive aphasia with structural neuroimagingJolina Lombardi, Benjamin Mayer, Elisa Semler, et al.
European Journal of Neurology|March 12, 2024
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD)Philip Van Damme, Ammar Al-Chalabi, Peter M Andersen, et al.
Nature Communications|March 27, 2025
CREB3 gain of function variants protect against ALSSalim Megat, Christine Marques, Marina Hernán-Godoy, et al.
Pageof 12